滴毒素困境:在痴呆症中诊断毒性
Parth Sushil Bajoria1, Vinod Nookala2
1GMERS Medical College and Hospital, Gandhinagar, India.
The Journal of innovations in cardiac rhythm management
|April 18, 2025
概括
迪戈辛毒性虽然不太常见,但仍然是一个风险,特别是在老年人中. 定期监测,而不仅仅是在毒性发作期间,对于预防致命结果至关重要.
科学领域:
- 心脏病学 心脏病学
- 临床药理学 临床药理学
- 毒理学 毒理学 毒理学
背景情况:
- 迪戈辛是一种心脏糖化物,具有狭窄的治疗指数,增加毒性风险.
- 老年患者由于多药和功能障碍,特别容易受到狄戈辛毒性影响.
- 虽然狄戈辛的使用量已经减少,但对毒性保持警仍然至关重要.
研究的目的:
- 为了在接受 digoxin 免疫 Fab.治疗的老年患者中呈现出 digoxin 毒性病例.
- 审查狄戈辛免疫Fab在慢性毒性的作用和局限性.
- 强调定期监测狄戈辛的重要性.
主要方法:
- 一个77岁的痴呆症妇女的病例介绍,患有痴呆症和提升的狄戈辛水平.
- 追溯审查类似的病例管理与或没有消毒素免疫Fab.
- 对治疗结果和监测策略的分析.
主要成果:
- 患有狄戈辛水平升高的患者成功地接受了狄戈辛免疫Fab的治疗.
- 该审查提供了关于免疫Fab在慢性狄戈辛毒性中使用的见解.
- 作为预防措施,突出强调了持续的狄戈辛监测.
结论:
- 迪戈辛免疫Fab可以有效治疗迪戈辛毒性.
- 定期监测狄戈辛水平对于预防严重毒性和死亡至关重要.
- 临床警是必要的,特别是在患有并发病的老年患者中.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.0K
10:01High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening
Published on: March 31, 2022
3.0K
相关概念视频
Heart Failure Drugs: Inotropic Agents
405
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
405
Dementia
65
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
65
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Myasthenia Gravis: Diagnostic Tests
538
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
538
Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
Depolarizing Blockers: Pharmocokinetics
289
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
289
